Anika Therapeutics, Inc. (ANIK)

Market Cap	238.87M
Revenue (ttm)	164.17M
Net Income (ttm)	-97.52M
Shares Out	14.65M
EPS (ttm)	-6.62
PE Ratio	n/a
Forward PE	38.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	204,352
Open	16.15
Previous Close	16.33
Day's Range	16.01 - 17.04
52-Week Range	15.83 - 29.12
Beta	0.90
Analysts	Buy
Price Target	24.50 (+50.22%)
Earnings Date	Oct 31, 2024

About ANIK

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Apr 29, 1993
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIK
• Website: https://www.anika.com

Financial Performance

In 2023, Anika Therapeutics's revenue was $166.66 million, an increase of 6.67% compared to the previous year's $156.24 million. Losses were -$82.67 million, 456.3% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for ANIK stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 50.22% from the latest price.

Price Target

$24.5

(50.22% upside)

Analyst Consensus: Buy